TY - JOUR
T1 - Precision medicine in COPD
T2 - Where are we and where do we need to go?
AU - Sidhaye, Venkataramana K.
AU - Nishida, Kristine
AU - Martinez, Fernando J.
N1 - Funding Information:
Support statement: Supported by R01HL124099 (to V.K. Sidhaye) and SPIROMICS, which was supported by contracts from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from AstraZeneca/MedImmune, Bayer, Bellerophon Therapeutics, Boehringer-Ingelheim Pharmaceuticals, Inc., Chiesi Farmaceutici SpA., Forest Research Institute, Inc., GlaxoSmithKline, Grifols Therapeutics, Inc., Ikaria, Inc., Nycomed GmbH, Takeda Pharmaceutical Company, Novartis Pharmaceuticals Corporation, ProterixBio, Regeneron Pharmaceuticals, Inc., Sanofi and Sunovion. Funding information for this article has been deposited with the Crossref Funder Registry.
Funding Information:
Theravance (personal fee honoraria and non-personal travel support for COPD advisory boards), personal fees and non-financial support from Genentech (personal fee and non-personal travel support for a COPD advisory board and non-financial support for an asthma data safety monitoring board), personal fees and non-financial support from GlaxoSmithKline (personal fee honoraria and non-personal travel support for COPD advisory boards, non-personal travel support for a study steering committee and an ERS presentation, and academic co-authorship for a data safety monitoring board), personal fees and non-financial support from Inova Fairfax Health System, Miller Communications, the National Association for Continuing Education, PeerView Communications, Prime Communications, the Puerto Rican Respiratory Society and Chiesi (personal fee honoraria and non-personal travel support for COPD CME programmes), personal fees from Inthought Research (personal fee honoraria for a COPD/asthma teleconference), personal fees from MD Magazine (personal fee honorarium and non-personal travel support for a COPD CME programme), personal fees and non-financial support from Novartis (personal fees honoraria and non-personal travel support for a COPD advisory board and international meeting COPD disease presentations), personal fees from Unity (personal fee honoraria for a COPD teleconference), personal fees from the American Thoracic Society (personal fee honoraria for being deputy editor of the AJRCCM), and a grant from the National Institutes of Health (COPD UO1/ RO1).
Publisher Copyright:
© ERS 2018.
PY - 2018/9/30
Y1 - 2018/9/30
N2 - Chronic obstructive pulmonary disease (COPD) was the fourth leading cause of death worldwide in 2015. Current treatments for patients ease discomfort and help decrease disease progression; however, none improve lung function or change mortality. COPD is heterogeneous in its molecular and clinical presentation, making it difficult to understand disease aetiology and define robust therapeutic strategies. Given the complexity of the disease we propose a precision medicine approach to understanding and better treating COPD. It is possible that multiOMICs can be used as a tool to integrate data from multiple fields. Moreover, analysis of electronic medical records could aid in the treatment of patients and in the predictions of outcomes. The Precision Medicine Initiative created in 2015 has made precision medicine approaches to treat disease a reality; one of these diseases being COPD.
AB - Chronic obstructive pulmonary disease (COPD) was the fourth leading cause of death worldwide in 2015. Current treatments for patients ease discomfort and help decrease disease progression; however, none improve lung function or change mortality. COPD is heterogeneous in its molecular and clinical presentation, making it difficult to understand disease aetiology and define robust therapeutic strategies. Given the complexity of the disease we propose a precision medicine approach to understanding and better treating COPD. It is possible that multiOMICs can be used as a tool to integrate data from multiple fields. Moreover, analysis of electronic medical records could aid in the treatment of patients and in the predictions of outcomes. The Precision Medicine Initiative created in 2015 has made precision medicine approaches to treat disease a reality; one of these diseases being COPD.
UR - http://www.scopus.com/inward/record.url?scp=85054097873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054097873&partnerID=8YFLogxK
U2 - 10.1183/16000617.0022-2018
DO - 10.1183/16000617.0022-2018
M3 - Article
C2 - 30068688
AN - SCOPUS:85054097873
SN - 0905-9180
VL - 27
JO - European Respiratory Review
JF - European Respiratory Review
IS - 149
ER -